Rinzimetostat 400 mg once daily selected as RP3D in combination with darolutamide for Himalayas-1 global Phase 3 registrational trial in post-abiraterone...
Lilly to gain ownership of Centessa's OX2R agonist pipeline designed to improve outcomes across sleep-wake disorders Centessa’s OX2R agonist pip...
COVALENT-211 Phase II enrolling insulin-deficient type 2 diabetes patients COVALENT-212 Phase II enrolling type 2 diabetes patients uncontrolled wit...
Mayo Clinic announces a gift of $75 million from the Thomas and Elizabeth Grainger family to support Bold. Forward. Unbound. in Rochester, Mayo Clinic's ...
Eli Lilly and Company announced detailed results from the TOGETHER-PsA open-label Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekiz...
UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo Nord...
Study conducted in collaboration with the Neuroregeneration Institute at McLean Hospital Autologous neuronal cell therapy for Parkinson’s diseas...
For the primary endpoint, retatrutide lowered A1C by an average of 1.7% to 2.0% across doses at 40 weeks in TRANSCEND-T2D-1 Participants taking retatrut...
Primary endpoint met in Phase 3 TALAPRO-3 study demonstrating a statistically significant and clinically meaningful reduction in risk of disease prog...
First-in-class oral therapy ATR-258 mimics the effects of exercise – driving fat loss, increasing muscle, and improving metabolism – with b...
New panel expands coverage for Alzheimer’s and Parkinson’s diseases including 15 new biomarkers developed with support from The Michael J. Fo...
Partnership marks the first introduction of Shield™ multi-cancer detection test in the region with availability across Hong Kong, Singapore and...
-Johnson & Johnson announced the arrival in Peru of a new pulsed field ablation (PFA) technology for the treatment of drug-refractory paroxysmal atri...
Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often e...
© 2026 Biopharma Boardroom. All Rights Reserved.
